Philogen SpAMIL:PHIL -0.21%61 Days Payable is 683.14 as of Dec. 2025, which is 24% below its 10-year median of 901.47. GuruFocus rates MIL:PHIL with a GF Score™ of 61/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 706 Biotechnology companies, Philogen SpA ranks better than 84.42% on this metric.
The historical rank and industry rank for Philogen SpA's Days Payable or its related term are showing as below:
MIL:PHIL'
s Days Payable Range Over the Past 10 Years
Min: 743.77 Med: 901.47 Max: 1160.42
Current: 826.83
During the past 6 years, Philogen SpA's highest Days Payable was 1160.42. The lowest was 743.77. And the median was 901.47.
MIL:PHIL's Days Payable is ranked better than 84.42% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs MIL:PHIL: 826.83
Philogen SpA's Days Payable
declined
from Dec. 2024 (1,130.56) to Dec. 2025 (683.14).
It may suggest that Philogen SpAaccelerated paying its suppliers.
Philogen SpA Days Payable Related Terms
Philogen SpA Days Payable Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Philogen SpA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Days Payable distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Philogen SpA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a Days Payable of 683.14 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Philogen SpA and its competitors. This is 24% below median its historical median of 901.47. Over the past decade, Philogen SpA's Days Payable has ranged from 743.77 to 1,160.42. According to the industry distribution chart, Philogen SpA ranks #110 out of 706 companies in the Biotechnology industry, placing it in the top 15.6%.
Is Philogen SpA's Days Payable too high?
Philogen SpA's current Days Payable of 683.14 is 24% below median its 10-year median of 901.47. Over the past 10 years, this metric has ranged from a low of 743.77 to a high of 1,160.42. The Biotechnology industry median Days Payable is 113.56. Philogen SpA's value of 683.14 is 501.6% above this industry median. Based on the distribution chart, Philogen SpA ranks #110 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #110 out of 706 companies for Days Payable. This places Philogen SpA in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Philogen SpA's value of 683.14 is 501.6% above this benchmark. Historically, Philogen SpA's own Days Payable has ranged from 743.77 to 1,160.42 over the past decade. While the company's 10-year median is 901.47 vs. the industry median of 113.56, Philogen SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current Days Payable of 683.14 is 501.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current Days Payable is 683.14, which is 24% below median its own 10-year median of 901.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.25 — trading 89.8% below its estimated fair value. The current Days Payable is 683.14, which is 24% below median its 10-year median of 901.47 and 501.6% above the Biotechnology industry median of 113.56. Philogen SpA's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Days Payable is 683.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.25 is trading 89.8% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Days Payable: 683.14 (24% below median its 10-year median of 901.47)
GF Value™: €227.22 vs. price of €23.25 (89.8% below fair value)
Industry Position: 501.6% above the Biotechnology median (#110 of 706)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score
Get the complete analysis for MIL:PHIL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
